Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie — Clinical Trial Site

104 Registered trials

49 Currently recruiting

Organisation

Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie

Location

Koszalin, Poland

Identifier

ORG-100041103

Address

Ul. Tytusa Chalubinskiego 7, 75-581, Poland

Departments

5701: Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
5702: Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej
5704: Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
5705: Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej
Chemotherapy clinic with a day ward
Department of Chemotherapy
Department of Clinical Oncology with a Subdivision of One-day Chemotherapy
Klinika Chemioterapii z oddziałem dziennym
Medical Oncology
N/A
NA
Oddzial Dzienny Chemioterapii
Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej
Oddzial Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
Oddział Dzienny Chemioterapii
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej,
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej.
Oddział Onkologii Klinicznej z Pododziałem Chemioterapii Jednodniowej
Oddział Onkologii Klinicznej z Pododziałem Chemioterapii Jednodnioweji
Oncology
Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie Oddział Dzienny Chemioterapii

Clinical trials at this site (104)

Search interface

Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-520927-26-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-11-24
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 KRAS G12C-mutant, Locally Advanced Unresectable or Meta 5 2025-09-26
Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting

2025-520672-26-00 Gastrointestinal Neoplasms 9 2025-09-16
A clinical study of treatments for non-small cell lung cancer (MK-3475-01H) Recruiting

2024-518761-10-00 Non-small Cell Lung Cancer 4 2025-08-25
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Metastatic castrate resistant prostate cancer - mCRPC 9 2025-08-12
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i… Recruiting

2024-516633-12-00 Locally advanced/ metastatic gastroesophageal junction 5 2025-06-30
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting

2024-512161-14-00 Breast Cancer 3 2025-01-14
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting

2023-504263-16-00 This is an extension study designed to provide continue 5 2023-05-25
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors Recruiting

2022-501563-40-00 Solid tumor cancer and lung cancer 1 2021-12-16